PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25916699-0	2015	Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways.	Celecoxib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	95-100	
25736380-5	2015	In vivo OSU-03012/sildenafil was more efficacious than treatment with celecoxib and sildenafil at killing tumor cells without damaging normal tissues and in parallel reduced expression of ABCB1 and ABCG2 in the normal brain.	Celecoxib	70-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	198-203	
26721701-1	2016	BACKGROUND: Preclinical results showing therapeutic effect and low toxicity of metronomic chemotherapy with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP).	Celecoxib	132-141	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	254-258	
26721701-1	2016	BACKGROUND: Preclinical results showing therapeutic effect and low toxicity of metronomic chemotherapy with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP).	Celecoxib	143-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	254-258	
23979202-1	2013	BACKGROUND: Metronomic chemotherapy (MCT) with cyclophosphamide (Cy) and celecoxib (Cel) has therapeutic efficacy and low toxicity profile in advanced breast cancer patients (ABCP), but no reliable biomarkers of response have been found yet that allow patient selection for treatment.	Celecoxib	73-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	175-179	
26417912-3	2015	In a dose dependent fashion celecoxib enhanced the ability of [sorafenib + sildenafil] to reduce expression of multiple chaperone proteins in parallel with lower levels of the drug efflux pumps ABCB1 and ABCG2.	Celecoxib	28-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	204-209	
25587329-0	2014	Celecoxib Up Regulates the Expression of Drug Efflux Transporter ABCG2 in Breast Cancer Cell Lines.	Celecoxib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	65-70	
25351347-8	2015	mRNA and protein expression levels of HIF-2alpha, ABCG2 and Oct-4 were significantly lower in the celecoxib and 5-FU/celecoxib combination groups (P<0.01) compared with those of the hypoxia control and 5-FU groups.	Celecoxib	98-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	50-55	
25351347-10	2015	In conclusion, the results of the present study indicated that celecoxib had anti-tumor effects, as it was shown to inhibit tumor cell growth via the inhibition of HIF-2alpha, ABCG2 and Oct-4.	Celecoxib	63-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	176-181	
25587329-3	2014	To clarify whether ABCG2 inhibition is involved in the sensitizing effect of celecoxib, we investigated whether the expression of ABCG2 in breast cancer cell lines, could be modulated by celecoxib.	Celecoxib	187-196	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	130-135	
25587329-6	2014	The COX-2 inhibitor celecoxib up-regulated the expression of ABCG2 mRNA in MCF-7 and MCF7-MX cells, which was accompanied by increased ABCG2 protein expression.	Celecoxib	20-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	61-66	
25587329-6	2014	The COX-2 inhibitor celecoxib up-regulated the expression of ABCG2 mRNA in MCF-7 and MCF7-MX cells, which was accompanied by increased ABCG2 protein expression.	Celecoxib	20-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	135-140	
25587329-7	2014	While celecoxib was able to block the 12-O-tetradecanoylphorbol-13-acetate (TPA)-mediated increase in COX-2 expression in MDA-MB-231 cells, it increased the expression of ABCG2 up to 4.27 times to the control level at mRNA level and with less intensity at protein level.	Celecoxib	6-15	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	171-176	
25587329-8	2014	Our findings provide evidence that celecoxib up-regulates ABCG2 expression in human breast cancer cells and proposed that ABCG2 is not involved in chemosensitizing effects of celecoxib.	Celecoxib	35-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	58-63	
23979202-1	2013	BACKGROUND: Metronomic chemotherapy (MCT) with cyclophosphamide (Cy) and celecoxib (Cel) has therapeutic efficacy and low toxicity profile in advanced breast cancer patients (ABCP), but no reliable biomarkers of response have been found yet that allow patient selection for treatment.	Celecoxib	84-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	175-179	
20422426-8	2011	It seemed that celecoxib inverted the effects of TPA on ABCG2 activity.	Celecoxib	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	56-61	
20422426-11	2011	The use of celecoxib for adjuvant therapy in cancer treatment may contribute to decreased resistance to chemotherapeutic drugs transported by ABCG2.	Celecoxib	11-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	142-147